| Name | Title | Contact Details |
|---|
Advanced Diagnostics Inc is a Anchorage, AK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
General Project Business Development Office is a Phillipsburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MEDX Ventures Group, founded in 2010, is an investment and management company with offices in Israel, USA and Europe. The company believes in active management (as opposed to passive investment), and is focusing on medical ventures and technologies in Israel while utilizing the Company`s unique X Model to include its core Development, Regulatory, Commercial and Finance team that manages a portfolio of ventures. MEDX Ventures Group capitalizes on its global presence while utilizing Israel`s unique research, development and operations capabilities in the field; As such the company focuses on smart investment, reduced risk, short time to market and efficient return on investment. MEDX Ventures Group is led by highly experienced medical device management and investment team from different aspects of the business to ensure the Company`s X Model is fully implemented and executed in each of its activities and ventures. In addition, the company continuously seeks alliances with global industry leaders, beginning in project development stage, to ensure medical innovations become the life changing reality for patients and providers, while becoming a profitable business to all stakeholders and generating attractive return for investors.
Pinnacle Products Inc is a Lakeville, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VeriTeQ's core technology evolved from implantable radio frequency identification (RFID) microchip technology used in the health care community for over two decades. This first-of-its-kind implantable RFID technology was cleared for use by the FDA in 2004 as a Class II medical device, originally to identify at-risk patients at the point of care. It has now evolved to help medical device manufacturers meet mandatory regulations outlined in the FDA's Safety & Innovation Act, signed into law in July 2012, and the FDA's Unique Device Identification (UDI) Final Rule. This technology is VeriTeQ's Q Inside Safety Technology. VeriTeQ's dosimeter technologies are used in the oncology suite and give an oncology team the ability to measure the dosage of radiation delivered to a patient on a per treatment basis. The data collected from our dosimeter technologies is invaluable when recording the total amount of radiation that a patient is exposed to during the entire treatment regimen, and the data can be used on a generic basis to develop future treatment regimens and evidence-based healthcare. VeriTeQ is developing an informatics and data analytics platform that will improve the type of medical device and treatment regimen data that can be used in many applications to improve patient healthcare and outcomes. Such examples include using VeriTeQ's UDI data in supply chain management for medical device manufacturers and healthcare institutions, quality and reimbursement controls for hospitals, and treatment regimen data for patients receiving chemotherapy and radiation therapy. VeriTeQ owns a rich portfolio of intellectual property protecting all of its current and future technologies.